Forecast

The analysts' average price target is +5,15€ (+1.070,45%). The median is +5,15€ (+1.070,45%).

Buy	4
Hold	1
Sell	0

News Go to news feed

Arcadia Biosciences secures $4 million through private placement

Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » More on de.investing.com
Arcadia Biosciences secures $4 million through private placement

Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » More on de.investing.com
Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor

Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » More on de.investing.com

Financials

In the last quarter, Arcadia Biosciences had revenue of 1.26m€ and net profit of −5.49m€

(EUR)	Jun 2026	YoY
Revenue	+1.26m	2,42%
Gross profit	+552.89k	3,28%
Net profit	−5.49m	45,16%
EBITDA	−5.49m	45,65%

Fundamentals

Metric	Value
Market capitalization	+683.04k€
Number of shares	1.55m
52-week high/low	+5,76€ - +0,33€
Dividends	No
Beta	0,55
P/E ratio	−0,06
PEG ratio	0,00
P/B ratio	+1,11
P/S ratio	+0,17

Company profile

Arcadia Biosciences, Inc. produziert und vermarktet in den Vereinigten Staaten Gesundheits- und Wellnessprodukte auf Pflanzenbasis. Das Unternehmen befasst sich mit der Entwicklung von Pflanzenverbesserungen, vor allem bei Weizen, um die Wirtschaftlichkeit der Landwirtschaft zu verbessern, indem es die Leistung der Pflanzen auf dem Feld erhöht und ihren Wert als Lebensmittelzutaten, Gesundheits- und Wellnessprodukte sowie ihre Eignung für industrielle Anwendungen steigert. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Davis, Kalifornien.

Name	Arcadia Biosciences
CEO	Thomas J. Schaefer
Headquarters	Davis, tx USA
Website	arcadiabio.com
Sector	Consumer Staples
Industry	Food Products
IPO	05/15/2015
Employees	8